Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study direc...

Full description

Bibliographic Details
Main Authors: Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane, Manohar Babu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Ophthalmology
Subjects:
Alcaftadine
allergic conjunctivitis
bepotastine
olopatadine
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=Dudeja

Internet

http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=9;spage=1400;epage=1404;aulast=Dudeja

Similar Items